tbuckley/cabot-search huggingface dataset:
Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain
Authors: Ivan Vucina
Journal: Annals of Internal Medicine (2017)

Letters5 December 2017Noninvasive Treatments for Acute, Subacute, and Chronic Low Back PainIvan Vucina, MDIvan Vucina, MDClínica las Condes, Universidad de Chile, Santiago de Chile, Chile (I.V.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0474 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Do Qaseem and colleagues (1) not believe that treatments for low back pain should differ according to the cause, which can range from a muscular problem to osteoporotic fracture of the spine?Reference1. Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians.. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:514-30. [PMID: 28192789]. doi:10.7326/M16-2367 LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Clínica las Condes, Universidad de Chile, Santiago de Chile, Chile (I.V.)Disclosures: The author has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0474. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNoninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians Amir Qaseem , Timothy J. Wilt , Robert M. McLean , Mary Ann Forciea , and Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Sandeep Vijan , Scott Manaker , and Amir Qaseem Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Donald M. Marcus Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Jeremy D. Whyman and Rosanne M. Leipzig Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Alain Braillon Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Mark Collen Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Donald R. Murphy , Michael J. Schneider , Christopher G. Bise , and Brian Justice Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain Lisa H. Le and Robert G. Badgett Metrics 5 December 2017Volume 167, Issue 11Page: 833KeywordsConflicts of interestDisclosureLower back painSpine ePublished: 5 December 2017 Issue Published: 5 December 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Assessment of HIV molecular surveillance capacity in the European Union, 2016
Authors: Patrick Keating, Anastasia Pharris, Katrin Leitmeyer, Stefania De Angelis, Annemarie Wensing, Andrew J Amato-Gauci, Eeva Broberg
Journal: Eurosurveillance (2017)

IntroductionExpanding access to HIV antiretroviral treatment is expected to decrease HIV incidence and acquired immunodeficiency syndrome (AIDS) mortality. However, this may also result in increased HIV drug resistance (DR). Better monitoring and surveillance of HIV DR is required to inform treatment regimens and maintain the long term effectiveness of antiretroviral drugs. As there is currently no formal European Union (EU)-wide collection of HIV DR data, this study aimed to assess the current HIV molecular surveillance capacity in EU/European Economic Area (EEA) countries in order to inform the planning of HIV DR monitoring at EU level. Methods: Thirty EU/EEA countries were invited to participate in a survey on HIV molecular surveillance capacity, which also included laboratory aspects. Results: Among 21 responding countries, 13 reported using HIV sequence data (subtype and/or DR) for surveillance purposes at national level. Of those, nine stated that clinical, epidemiological and sequence data were routinely linked for analysis. Discussion/conclusion: We identified similarities between existing HIV molecular surveillance systems, but also found important challenges including human resources, data ownership and legal issues that would need to be addressed.Information on capacities should allow better planning of the phased introduction of HIV DR surveillance at EU/EEA level.
Positivity Rates of Non-Sentinel Lymph Nodes (NSLN) After Sentinel Lymph Node (SLN) Analysis by OSNA (One Step Nuclear Acid Amplification) in Patients With Breast Cancer
Authors: S. Doddi, M. Shahram, G. Demissie, R. Hafeez, A. Nagarajakumar, T. Singhal, P. Sinha
Journal: International Journal of Surgery (2017)
Mismatched unrelated donor allogeneic stem cell transplant for high risk haematological malignancy: A single centre experience
Authors: Heshani Mediwake, Cameron Curley, Jason Butler, Angela Mclean, Siok Tey, Geoffrey R. Hill, Anthony Morton, Ashish Misra, Elango Subramoniapillai, Simon Durrant, Glen A. Kennedy
Journal: Blood Cancer Journal (2017)

Human leukocyte antigen (HLA) matched allogeneic stem cell transplant (SCT) is an established curative treatment for various haematologic malignancies1. However, a fully matched HLA-donor may still not be identified in a significant proportion of patients. Those who do not have an available HLA-matched donor can still potentially undertake transplantation utilizing an alternative donor source, including mismatched unrelated donors (MMUD), umbilical cord blood (UCB) or haploidentical donors2. Although MMUD SCT is associated with increased risk of both graft versus host disease (GVHD) and non-relapse mortality (NRM), MMUD have still historically been utilized as alternative donor sources due to ease of donor availability3.
Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery
Authors: Yuan Wan, Lixue Wang, Chuandong Zhu, Qin Zheng, Guoxiang Wang, Jinlong Tong, Yuan Fang, Yiqiu Xia, Gong Cheng, Xia He, Si-Yang Zheng
Journal: Cancer Research (2017)

Abstract Extracellular nanovesicles (ENV) released by many cells contain lipids, proteins, and nucleic acids that contribute to intercellular communication. ENVs have emerged as biomarkers and therapeutic targets but they have also been explored as drug delivery vehicles. However, for the latter application, clinical translation has been limited by low yield and inadequate targeting effects. ENV vectors with desired targeting properties can be produced from parental cells engineered to express membrane-bound targeting ligands, or they can be generated by fusion with targeting liposomes; however, neither approach has met clinical requirements. In this study, we demonstrate that mechanical extrusion of approximately 107 cells grafted with lipidated ligands can generate cancer cell–targeting ENV and can be prepared in approximately 1 hour. This rapid and economic approach could pave the way for clinical implementation in the future. Significance: A new and rapid method for production of drug-targeting nanovesicles has implications for cancer treatment by chimeric antigen receptor T cells and other therapies. Cancer Res; 78(3); 798–808. ©2017 AACR.
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma
Authors: Jacques Grill, Maura Massimino, Eric Bouffet, Amedeo A. Azizi, Geoffrey McCowage, Adela Cañete, Frank Saran, Marie-Cécile Le Deley, Pascale Varlet, Paul S. Morgan, Tim Jaspan, Chris Jones, Felice Giangaspero, Helen Smith, Josep Garcia, Markus C. Elze, Raphaël F. Rousseau, Lauren Abrey, Darren Hargrave, Gilles Vassal
Journal: Journal of Clinical Oncology (2018)

Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, multicenter, open-label HERBY trial ( ClinicalTrials.gov identifier: NCT01390948) enrolled patients age ≥ 3 years to ≤ 18 years with localized, centrally neuropathology-confirmed, nonbrainstem HGG. Eligible patients were randomly assigned to receive RT + TMZ (RT: 1.8 Gy, 5 days per week, and TMZ: 75 mg/m2 per day for 6 weeks; 4-week treatment break; then up to 12 × 28-day cycles of TMZ [cycle 1: 150 mg/m2 per day, days 1 to 5; cycles 2 to 12: 200 mg/m2 per day, days 1 to 5]) with or without BEV (10 mg/kg every 2 weeks). The primary end point was event-free survival (EFS) as assessed by a central radiology review committee that was blinded to treatment. We report findings of EFS at 12 months after the enrollment of the last patient. Results One hundred twenty-one patients were enrolled (RT+TMZ [n = 59]; BEV plus RT+TMZ [n = 62]). Central radiology review committee-assessed median EFS did not differ significantly between treatment groups (RT+TMZ, 11.8 months; 95% CI, 7.9 to 16.4 months; BEV plus RT+TMZ, 8.2 months; 95% CI, 7.8 to 12.7 months; hazard ratio, 1.44; P = .13 [stratified log-rank test]). In the overall survival analysis, the addition of BEV did not reduce the risk of death (hazard ratio, 1.23; 95% CI, 0.72 to 2.09). More patients in the BEV plus RT+TMZ group versus the RT+TMZ group experienced one or more serious adverse events (n = 35 [58%] v n = 27 [48%]), and more patients who received BEV discontinued study treatment as a result of adverse events (n = 13 [22%] v n = 3 [5%]). Conclusion Adding BEV to RT+TMZ did not improve EFS in pediatric patients with newly diagnosed HGG. Our findings were not comparable to those of previous adult trials, which highlights the importance of performing pediatric-specific studies.
A community-based non-randomised controlled intervention programme for blood pressure control in China
Authors: Mengying Wang, Tao Wu, Yonghua Hu, Weihua Cao, Siyan Zhan, Jun Lv, Wenjing Gao, Canqing Yu, Shengfeng Wang, Geng Wang, Jin Wang, Liqiang Dai, Liming Li
Journal: The Lancet (2017)
Dissecting the Role of Individual Bcl-2 Members in Response and Resistance to Ibrutinib or Venetoclax in CLL
Authors: Fabio Brocco, Hanneke ter Burg, Stacey Fernandes, Constantine S. Tam, Francesco Forconi, Rachel M Guerra, Gregory Bird, Loren D Walensky, Jennifer R. Brown, Arnon P Kater, Eric Eldering
Journal: Blood (2017)
Absence of hybridization with the wild-type and mutant rpoB probes in the Genotype MTBDRplus assay detects ‘disputed’ rifampicin mutations
Authors: N.N. Abanda, J.Y. Djieugoué, V.S. Khadka, E.W. Pefura-Yone, W.F. Mbacham, G. Vernet, V.M. Penlap, Y. Deng, S.I. Eyangoh, D.W. Taylor, R.G.F. Leke
Journal: Clinical Microbiology and Infection (2017)
Abstract 12899: Predictive Value of Markers of Collagen Turnover for Systolic and Diastolic Heart Failure: The MESA Study
Authors: Daniel Duprez, Myron Gross, Jorge R Kizer, Joahim I Ix, William G Hundley, David R Jacobs
Journal: Circulation (2016)

Introduction: Markers of collagen turnover have prognostic value in heart failure (HF), but the predictive value of these markers for incident heart failure in asymptomatic subjects is unknown. Hypothesis: Collagen turnover markers (Procollagen Type III N-Terminal Propeptide (PIIINP) and Collagen Type I Carboxy-Terminal Telopeptide (ICTP)) may be associated with new onset of HF (total, systolic and diastolic HF) in subjects free of overt cardiovascular disease (CVD) at baseline. Methods: We used a nested case-control design in a multi-ethnic sample of 3147 subject initially aged 45-84 years and free of CVD. We assayed baseline serum PIIINP and ICTP concentrations using radio-immunoassay. Incident HF (n=196) was based on medical records through a median 12.1 years of follow-up. Systolic HF (HFrEF) was defined if ejection fraction (EF) &lt; 45 % and diastolic HF (HFpEF) if EF ≥ 45%. Poisson regressions were calculated using 2 models, adjusting for 1. Demographics (demog.) and estimated glomerular filtration (eGFrR) because ICTP is cleared by the kidney; 2. Model 1 + classical cardiovascular risk factors, and blood pressure and cholesterol lowering medication. Results: Mean (SD) ICTP was 3.38 ± 1.77 μg/L and Mean (SD) PIIINP was 5.48 ± 2.04 μg/L. Among 196 new HF cases, 95 were systolic HF (HFrEF) and 86 were diastolic HF (HFpEF); the 15 HF cases with no ejection fraction recorded were omitted from subtype analysis. In Poisson regression during 12.1 year follow-up (Table 1), Model 1 associations of ICTP and PIIINP with total HF and HFpEF were substantially attenuated in Model 2, although PIINP remained significantly associated with HFpEF. Conclusion: PIIINP as a marker of collagen turnover is predictive for incident HFpEF, in initially asymptomatic subjects free of overt cardiovascular disease, independently of classical cardiovascular risk factors.
Association Between Hypercoagulable Conditions and Calciphylaxis in Patients With Renal Disease
Authors: Allison S. Dobry, Lauren N. Ko, Jessica St John, J. Mark Sloan, Sagar Nigwekar, Daniela Kroshinsky
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Calciphylaxis is a rare skin disease with high morbidity and mortality that frequently affects patients with renal disease. Hypercoagulable conditions are frequently observed in both patients with calciphylaxis and those with chronic kidney disease (CKD), complicating our understanding of which hypercoagulable conditions are specific to calciphylaxis. <h3>Objective</h3> To identify hypercoagulable conditions that are risk factors for developing calciphylaxis while controlling for CKD. <h3>Design, Setting, and Participants</h3> This was a case-control study, comparing the hypercoagulability status of patients with calciphylaxis and with renal disease with that of a matched control population at 2 large urban academic hospitals in Boston, Massachusetts. Retrospective medical record review of laboratory values was performed to identify patients with hypercoagulable conditions. Case and control patients were further stratified based on both severity of CKD and warfarin. Patients with a dermatologic diagnosis of calciphylaxis between 2006 and 2014 and concomitant CKD were included as cases (n = 38). Three controls (n = 114) per case patient with CKD were included, and were matched by age, sex, and race. <h3>Main Outcomes and Measures</h3> The rate of various hypercoagulable states (ie, antithrombin III [ATIII] deficiency, protein C and S deficiency, factor V Leiden mutation, prothrombin gene mutation [<i>G20210A</i>], elevated factor VIII level, lupus anticoagulant, anti-IgG or IgM cardiolipin antibodies, heparin-induced thrombocytopenia antibodies, and elevation of homocysteine) in patients with calciphylaxis compared with their matched controls. <h3>Results</h3> Of the calciphylaxis cohort, 28 (58%) were female and 18 (55%) were non-Hispanic white. Among all patients, lupus anticoagulant (13 [48%] positive in cases vs 1 [5%] in controls;<i>P</i> = .001), protein C deficiency (9 [50%] vs 1 [8%];<i>P</i> = .02), and combined thrombophilias (18 [62%] vs 10 [31%];<i>P</i> = .02) were found to be significantly associated with calciphylaxis. In a subanalysis of patients with stage 5 CKD, only lupus anticoagulant (12 [53%] vs 9 [0%];<i>P</i> = .01) and combined thrombophilia (15 [63%] vs 1 [8%];<i>P</i> = .004) remained significantly associated with calciphylaxis. In a separate subanalysis of warfarin-unexposed patients, only lupus anticoagulant (7 [50%] vs 1 [6%];<i>P</i> = .01) and protein C deficiency (5 [46%] vs 10 [0%];<i>P</i> = .04) remained significantly associated with calciphylaxis. <h3>Conclusions and Relevance</h3> Presence of lupus anticoagulant and combined thrombophilias are risk factors for the development of calciphylaxis in patients with late-stage renal disease. Clinicians should be aware of these associations in patients with impaired kidney function and may consider increased screening and appropriate anticoagulation treatment to reduce the risk of calciphylaxis development.
Comprehensive Evaluation of the Learning Curve for Peroral Endoscopic Myotomy
Authors: Zuqiang Liu, Xiaocen Zhang, Wei Zhang, Yiqun Zhang, Weifeng Chen, Wenzheng Qin, Jianwei Hu, Mingyan Cai, Pinghong Zhou, Quanlin Li
Journal: Clinical Gastroenterology and Hepatology (2017)
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk
Authors: Benjamin M. Scirica, Ofri Mosenzon, Deepak L. Bhatt, Jacob, A. Udell, Ph Gabriel Steg, Darren K. McGuire, KyungAh Im, Estella Kanevsky, Christina Stahre, Mikaela Sjöstrand, Itamar Raz, Eugene Braunwald
Journal: JAMA Cardiology (2017)

An elevated level of urinary albumin to creatinine ratio (UACR) is a marker of renal dysfunction and predictor of kidney failure/death in patients with type 2 diabetes. The prognostic use of UACR in established cardiac biomarkers is not well described.
Intranasal dexmedetomidine with and without buccal midazolam for procedural sedation in autistic children: a double-blind randomised controlled trial
Authors: Bi Lian Li, Vivian Man-ying Yuen, Na Zhang, Huan Huan Zhang, Xiao Hua Guo, Jun Xiang Huang, Jeff Miller, XingRong Song
Journal: The Lancet (2017)
Abstract 14059: Ranolazine for Rhythm Control in Atrial Fibrillation: a Systematic Review and Meta-Analysis
Authors: Federico Guerra, Andrea Romandini, Alessandro Barbarossa, Alessandro Capucci
Journal: Circulation (2016)

Introduction: Current available options for rhythm control strategy in atrial fibrillation (AF) are burdened by sub-optimal efficacy and potentially serious adverse events. For this reason, the dev...
Abstract 13990: Early Clinical Experience of Trans-Catheter Closure of Patent Ductus Arteriosus in Extremely Premature Neonates
Authors: Ranjit Philip, Kaitlin Balduf, Kristin Washington, Sandeep Chilakala, Alejandro Arevalo, Thomas Fagan, B. Rush Waller, Shyam Sathanandam
Journal: Circulation (2016)

Introduction: Children born prematurely often have a patent ductus arteriosus (PDA). Surgical ligation of the PDA is standard when pharmacologic therapy fails. Trans-catheter closure of PDA (TCCPDA) in premature neonates is a relatively new technique. Hypothesis: To describe our early clinical experience of TCCPDA in premature neonates who require positive pressure ventilation (PPV) and to identify risk factors for poor respiratory outcomes. Methods: A retrospective review was performed. A respiratory severity score (RSS) was calculated for all patients. The change in the RSS post-procedure and the time taken for return to pre-procedure RSS were used as outcome variables. Patients with pulmonary artery systolic pressure &gt;50% of the systolic blood pressure were considered to have pulmonary hypertension (PHT). Results: Thirty premature neonates (25.7±2.8 weeks’ gestation, birth weight=756±284 g) that were PPV dependent with or without PHT were referred for TCCPDA at 55.5±32.2 days of age, weighing 1.67±0.54 Kg. Procedures were performed using only femoral venous access under echo and fluoroscopic guidance. The device used for closure included the 4mm Amplatzer Vascular Plug-II (AVP-II) in 10, 6 mm AVP-II in 10, 8mm AVP-II in 3, 4mm AVP-4 in 1 and MVP-5Q device in 6 patients. The procedure and fluoroscopic times were 83.7±56.8 and 12.8±11.6 minutes respectively. The radiation and contrast doses were 52.8±34.2 mGy and 2.8±1.5 mL/Kg respectively. The baseline RSS and QP:QS ratio were 3.9±3.3 and 2.2±0.8 respectively. The presence of PHT was the only predictor for a longer time to return to pre-procedure RSS (18 vs. 87 hours; OR=5.4, 95% CI:2.2-9.4, P&lt;0.001) with a 68.8±32.6% increase in RSS (P&lt;0.01). There was one procedure-related mortality. One patient, weighing1.06 Kg, developed left pulmonary artery stenosis following device closure. The device embolized in another patient 6 hours post-procedure. Both these devices were snared and retrieved. No other complications were noted during the procedure or on follow-up (mean 1.8 ± 0.8 years). No patients had residual PDA on follow-up echocardiogram. Conclusions: It is feasible to perform trans-catheter closure of PDAs in premature neonates. Presence of PHT prolongs the need for PPV after PDA closure.
Abstract 18558: A Puzzling Case of Dyspnea on Exertion
Authors: Srinath Adusumalli, Neel P Chokshi
Journal: Circulation (2016)

A 59 year-old Caucasian male with a past medical history of presumed pulmonary sarcoidosis, asthma, hypothyroidism, and allergic rhinitis presented to our institution with dyspnea on exertion. One ...
Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial
Authors: Michael F. Grunebaum, Hanga C. Galfalvy, Tse-Hwei Choo, John G. Keilp, Vivek K. Moitra, Michelle S. Parris, Julia E. Marver, Ainsley K. Burke, Matthew S. Milak, M. Elizabeth Sublette, Maria A. Oquendo, J. John Mann
Journal: American Journal of Psychiatry (2017)

Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder.In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75). The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0). Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score. Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up.Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.